共 50 条
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
被引:1
|作者:
Kristeleit, Rebecca Sophie
Brown, Nicholas F.
Hess, Dagmar
Joerger, Markus
Von Moos, Roger
Rodon, Jordi
Hierro, Cinta
Childs, Alexa
Stathis, Anastasios
Dimitrijevic, Sasa
Stumm, Michael
Herrmann, Richard
Sessa, Cristiana
Bize, Vincent
Hess, Viviane
Wicki, Andreas
机构:
[1] UCL, Inst Canc, London, England
[2] UCL, London, England
[3] Kantonsspital St Gallen, Eggersriet, Switzerland
[4] Cantonal Hosp, St Gallen, Switzerland
[5] VHIO, Barcelona, Spain
[6] IOSI Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[7] PIQUR Therapeut AG, Basel, Switzerland
[8] Piqur Pharma, Basel, Switzerland
[9] Univ Hosp, Riehen, Switzerland
[10] IOSI, Bellinzona, Switzerland
[11] SAKK Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland
[12] Univ Spital Basel, Basel, Switzerland
[13] Univ Basel Hosp, CH-4031 Basel, Switzerland
关键词:
D O I:
10.1200/jco.2015.33.15_suppl.2592
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
2592
引用
收藏
页数:1
相关论文